Entry into a Material Definitive Agreement. As previously disclosed, on August 3, 2026, Harrow, Inc. (the "Company") entered into an Asset Purchase Agreement (the "Original Purchase Agreement") with Viatris Inc. ("Viatris") relating to the acquisition of TYRVAYA ® (varenicline solution) nasal spray 0.03 mg ("TYRVAYA"), a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. On October 1, 2026, the Company and Viatris amended and restated the Original Pu…

Completion of Acquisition or Disposition of Assets. Pursuant to the Purchase Agreement, the Company agreed to acquire rights to TYRVAYA in all countries of the world other than Japan. The assets acquired include the related new drug application and other regulatory approvals, intellectual property, technology, inventory and related contracts (collectively, the "Acquired Assets"), and the Company agreed to assume certain specified liabilities relating to the Acquired Assets (the "Assumed Liabi…

Regulation FD Disclosure. On October 5, 2026, the Company issued a press release announcing the completion of the acquisition of the Acquired Assets. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or o…

Chief Accounting Officer — Randall E. Pollard: The Chief Accounting Officer ceased serving, but the CFO immediately assumed the role without additional compensation, indicating an orderly internal succession rather than a shock departure.

Results of Operations and Financial Condition. On August 10, 2026, Harrow, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the quarter ended June 30, 2026 and providing an update on recent corporate developments. The press release and letter to stockholders are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.

Entry into a Material Definitive Agreement. On August 3, 2026, Harrow, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Viatris Inc. (“Viatris”), pursuant to which the Company agreed to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray 0.03 mg (“TYRVAYA”), a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (the “Acquisition”). Under the terms of the Purchase Agreement, the Company w…

Regulation FD Disclosure. On August 6, 2026, the Company issued a press release announcing the execution of the Purchase Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise sub…

Results of Operations and Financial Condition. On May 11, 2026, Harrow, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the quarter ended March 31, 2026 and providing an update on recent corporate developments. The press release and letter to stockholders are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.

Other Events. On March 27, 2026, the Company completed the sale of the New Notes in a private offering (the “Offering”) to persons reasonably believed to be “qualified institutional buyers” in the United States, as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act. The Company received net proceeds from the Offering, after…

Entry Into a Material Definitive Agreement Purchase Agreement On March 24, 2026, Harrow, Inc. (the “Company”) entered into a purchase agreement, dated March 24, 2026 (the “Purchase Agreement”) with BTIG, LLC, as representative of the several initial purchasers named therein (collectively, the “Initial Purchasers”), in connection with its offer and sale of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”). The terms of the New Notes sold purs…

Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Other Events. On March 24, 2026, Harrow, Inc. (the “Company”) issued a press release announcing the pricing of its offering of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”) in a private offering (the “Offering”) to persons reasonably believed to be “qualified institutional buyers” in the United States, as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.S. persons outside the…

Other Events. On March 24, 2026, Harrow, Inc. (the “Company”) issued a press release to announce the launch of its offer to sell $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”) in a private offering (the “Offering”) to persons reasonably believed to be “qualified institutional buyers” in the United States, as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.S. persons outside th…

Results of Operations and Financial Condition. On March 2, 2026, Harrow, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the year and quarter ended December 31, 2025 and providing an update on recent corporate developments. The press release and letter to stockholders are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.

Results of Operations and Financial Condition. On February 2, 2026, Harrow, Inc. (the “Company”) issued a press release, which, among other things, reaffirmed the Company’s full-year 2025 revenue guidance of between $270 million and $280 million. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this

Chief Commercial Officer — Patrick W. Sullivan: Patrick W. Sullivan was promoted to Chief Commercial Officer from Head of Commercial.

Completion of Acquisition or Disposition of Assets. On November 17, 2025, Harrow, Inc. (the “Company”) completed the previously announced acquisition of Melt Pharmaceuticals, Inc. (“Melt”) pursuant to the Agreement and Plan of Merger, dated September 24, 2025 (the “Merger Agreement”), by and among the Company, Harrow Acquisition Sub, Inc., Melt, and the stockholder representative. The material terms of the Merger Agreement and the related milestone payment agreement were previously described…

Any such shares would be issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.

Results of Operations and Financial Condition. On November 10, 2025, Harrow, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the period ended September 30, 2025, and an update on recent corporate events. The press release and letter to stockholders are being furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.

President and Chief Executive Officer — John Saharek: Mr. Saharek ceased serving as President and CEO of ImprimisRx, LLC and certain affiliated entities.

of the Original Report. No other changes are being made to the Original Report. For convenience, investors are reminded that the Original Report disclosed the Company’s entry into the Merger Agreement with Melt and noted that the Company expected to file the full text of the definitive agreements as an exhibit to its Quarterly Report on Form 10-Q for the three months ending September 30, 2025.

Entry Into a Material Definitive Agreement. On September 26, 2025, Harrow, Inc., (the “ Company ”), and subsidiaries of the Company as guarantors (“ Subsidiary Guarantors ”) entered into a Credit Agreement (the “ New Credit Agreement ”) with Fifth Third Bank, National Association, as administrative agent for itself and the other lenders, the letter of credit issuer, the swing line lender, the sole lead arranger and the sole bookrunner (“ Fifth Third ”) providing for a senior secured revolving…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. To the extent applicable, the disclosure included in

If the applicable milestone is reached, the Common Stock would be issued to Melt stockholders pursuant to the exemption from the registration requirements provided in Section 4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”) for transactions by an issuer not involving any public offering. Accordingly, the Common Stock issuable to Melt stockholders has not been registered under the Securities Act and may not be offered or sold in the United States except pursuant to an…

Entry Into a Material Definitive Agreement. On September 8, 2025, Harrow, Inc., a Delaware corporation (the “ Company ”), reported that it had entered into a non-binding indication of interest (“ IOI ”) to acquire the equity interests in Melt Pharmaceuticals, Inc., a Delaware corporation (“ Melt ”), not already owned by the Company. Consistent with the IOI, on September 24, 2025, the Company entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Harr…